{"id":"https://openalex.org/W2887029617","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9062","title":"Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.","display_name":"Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.","publication_year":2018,"publication_date":"2018-05-20","ids":{"openalex":"https://openalex.org/W2887029617","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9062","mag":"2887029617"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2018.36.15_suppl.9062","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.9062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5082517668","display_name":"D. Ross Camidge","orcid":"https://orcid.org/0000-0003-3430-3213","observed_orcids":["https://orcid.org/0000-0003-3430-3213"]},"institutions":[{"id":"https://openalex.org/I51713134","display_name":"University of Colorado Anschutz","ror":"https://ror.org/03wmf1y16","country_code":"US","type":"education","lineage":["https://openalex.org/I51713134"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Ross Camidge","raw_affiliation_strings":["Medical Oncology Department, University of Colorado, Aurora, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, University of Colorado, Aurora, CO;","institution_ids":["https://openalex.org/I51713134"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004712121","display_name":"Gregory A. Otterson","orcid":"https://orcid.org/0000-0001-9877-8512","observed_orcids":["https://orcid.org/0000-0001-9877-8512"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory Alan Otterson","raw_affiliation_strings":["The James Comprehensive Cancer Center, Ohio State University, Columbus, OH;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The James Comprehensive Cancer Center, Ohio State University, Columbus, OH;","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088474933","display_name":"Jeffrey William Clark","orcid":"https://orcid.org/0000-0001-9524-3600","observed_orcids":["https://orcid.org/0000-0001-9524-3600"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey W. Clark","raw_affiliation_strings":["Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087923582","display_name":"Sai\u2010Hong Ignatius Ou","orcid":"https://orcid.org/0000-0002-1764-4975","observed_orcids":["https://orcid.org/0000-0002-1764-4975"]},"institutions":[{"id":"https://openalex.org/I204250578","display_name":"University of California, Irvine","ror":"https://ror.org/04gyf1771","country_code":"US","type":"education","lineage":["https://openalex.org/I204250578"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sai-Hong Ignatius Ou","raw_affiliation_strings":["Medicine, Hematology/Oncology Department, University of California, Irvine, Orange, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicine, Hematology/Oncology Department, University of California, Irvine, Orange, CA;","institution_ids":["https://openalex.org/I204250578"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022384270","display_name":"Jared M. Weiss","orcid":"https://orcid.org/0000-0003-2961-4447","observed_orcids":["https://orcid.org/0000-0003-2961-4447"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jared Weiss","raw_affiliation_strings":["School of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Medicine, University of North Carolina-Chapel Hill, Chapel Hill, NC;","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088938428","display_name":"Steven Ades","orcid":"https://orcid.org/0000-0002-7077-1842","observed_orcids":["https://orcid.org/0000-0002-7077-1842"]},"institutions":[{"id":"https://openalex.org/I2801980284","display_name":"University of Vermont Medical Center","ror":"https://ror.org/04cewr321","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801980284"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven Ades","raw_affiliation_strings":["Hematology/Oncology, The University of Vermont Medical Center, Burlington, VT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, The University of Vermont Medical Center, Burlington, VT;","institution_ids":["https://openalex.org/I2801980284"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091231536","display_name":"Umberto Conte","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Umberto Conte","raw_affiliation_strings":["Pfizer, Inc., New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc., New York, NY;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035532245","display_name":"Yiyun Tang","orcid":"https://orcid.org/0000-0001-9810-1288","observed_orcids":["https://orcid.org/0000-0001-9810-1288"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiyun Tang","raw_affiliation_strings":["Pfizer Inc., La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., La Jolla, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051641299","display_name":"Sherry Chia-E Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sherry Chia-E Wang","raw_affiliation_strings":["Pfizer Inc., La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., La Jolla, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103042869","display_name":"Danielle A. Murphy","orcid":"https://orcid.org/0000-0003-1448-9444","observed_orcids":["https://orcid.org/0000-0003-1448-9444"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle Murphy","raw_affiliation_strings":["Pfizer Inc., La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., La Jolla, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061648315","display_name":"Keith D. Wilner","orcid":"https://orcid.org/0000-0002-2276-7865","observed_orcids":["https://orcid.org/0000-0002-2276-7865"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith D. Wilner","raw_affiliation_strings":["Pfizer Inc., La Jolla, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., La Jolla, CA;","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082389042","display_name":"Liza Cosca Villaruz","orcid":"https://orcid.org/0000-0001-7456-523X","observed_orcids":["https://orcid.org/0000-0001-7456-523X"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liza Cosca Villaruz","raw_affiliation_strings":["Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA;","institution_ids":["https://openalex.org/I4210134769"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":80,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"36","issue":"15_suppl","first_page":"9062","last_page":"9062"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/met-amplification","display_name":"MET amplification","score":0.9869999885559082},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8569999933242798},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8180000185966492},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7739999890327454},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6549999713897705},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.5070000290870667},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.8769999742507935},{"id":"https://openalex.org/keywords/best-overall-response","display_name":"best overall response","score":0.8669999837875366},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6690000295639038}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9762167930603027},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9047048091888428},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.698887288570404},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.594228208065033},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.5886579751968384},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.5855307579040527},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5373761653900146},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5133330225944519},{"id":"https://openalex.org/C2779177807","wikidata":"https://www.wikidata.org/wiki/Q3658562","display_name":"non-small cell lung cancer (NSCLC)","level":4,"score":0.504602313041687},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.4535977244377136},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.41660773754119873},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.3608970046043396},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3531525731086731},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33337730169296265},{"id":"https://openalex.org/C81729549","wikidata":"https://www.wikidata.org/wiki/Q4649475","display_name":"A549 cell","level":3,"score":0.0},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2018.36.15_suppl.9062","doi":"https://doi.org/10.1200/jco.2018.36.15_suppl.9062","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2018.36.15_suppl.9062","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2439107762","https://openalex.org/W3133838590","https://openalex.org/W4312180573","https://openalex.org/W2967992516","https://openalex.org/W2610073600","https://openalex.org/W1970299210","https://openalex.org/W3153877271","https://openalex.org/W2569407036","https://openalex.org/W2923893167","https://openalex.org/W2626896592"],"abstract_inverted_index":{"9062":[0],"Background:":[1],"MET":[2,40,45,66,81,181,208,236,257],"amplification":[3],"(amp)":[4],"has":[5,33],"been":[6],"reported":[7],"in":[8,27,37,55,68,205,218],"a":[9],"subset":[10],"of":[11,39,53,65,141,162,228,264],"NSCLC":[12,233],"with":[13,57,87,223,232,234,245,256],"the":[14,19,188,224],"frequency":[15],"varying":[16],"depending":[17],"on":[18,105,212,372],"definition":[20],"used.":[21],"Crizotinib,":[22],"an":[23,50],"ALK/ROS1/MET":[24],"inhibitor":[25],"approved":[26],"ALK-":[28],"or":[29,114],"ROS1-positive":[30],"NSCLC,":[31],"also":[32],"proven":[34],"clinical":[35],"activity":[36,244],"cases":[38],"exon":[41,258],"14":[42,259,290],"alterations":[43,260],"and":[44,61,99,130,165,201,247,261],"amp.":[46,182],"Here":[47],"we":[48],"present":[49],"updated":[51],"analysis":[52],"crizotinib":[54,95,265],"pts":[56,86,175,210],"low,":[58],"medium":[59],"(med),":[60],"high":[62],"(hi)":[63],"levels":[64],"amp":[67,82,190,237],"advanced":[69],"NSCLC.":[70],"Methods:":[71],"In":[72],"this":[73,219],"ongoing,":[74],"open-label,":[75],"multicenter,":[76],"phase":[77],"1":[78,318,331,337,339,343],"trial":[79,270],"(NCT00585195),":[80],"was":[83,194,221,251],"locally":[84],"tested;":[85],"MET/CEP7":[88,117],"ratios":[89],"\u22651.8":[90],"were":[91,100,123,133,176,185],"eligible.":[92],"Pts":[93,231],"received":[94],"250":[96],"mg":[97],"BID":[98],"assigned":[101],"to":[102,125,136,154],"categories":[103],"based":[104],"low":[106],"(\u22651.8\u2013\u22642.2),":[107],"med":[108],"(":[109],">":[110,126],"2.2\u2013":[111,127],"<":[112,128],"5),":[113],"hi":[115,209,235],"(\u22655)":[116],"ratios.":[118],"The":[119,214],"latter":[120],"2":[121,314,319,344],"thresholds":[122],"revised":[124,189],"4":[129,325,332],"\u22654;":[131],"data":[132,169],"then":[134],"reanalyzed":[135],"better":[137],"delineate":[138],"predictive":[139],"biomarkers":[140],"response.":[142],"Selected":[143],"endpoints":[144],"included":[145],"best":[146],"overall":[147],"response":[148,156,163,295],"(BOR)":[149],"per":[150],"RECIST":[151],"v1.0,":[152],"time":[153],"tumor":[155],"(TTR),":[157],"progression-free":[158],"survival":[159],"(PFS),":[160],"duration":[161],"(DOR)":[164],"safety.":[166],"Results:":[167],"At":[168],"cutoff":[170],"(31":[171],"Oct":[172],"2017),":[173],"40":[174],"treated;":[177],"3":[178,207,287,333,338],"had":[179],"no":[180],"Baseline":[183],"characteristics":[184],"comparable":[186],"among":[187],"categories.":[191],"Median":[192,345,355],"TTR":[193],"8.0":[195],"wk":[196],"(range,":[197],"7.1\u20139.1).":[198],"BOR,":[199],"DOR,":[200,346],"PFS":[202],"are":[203],"shown":[204],"the.":[206],"remain":[211],"treatment.":[213],"adverse":[215],"event":[216],"profile":[217,227],"cohort":[220],"consistent":[222],"established":[225],"safety":[226],"crizotinib.":[229],"Conclusions:":[230],"(MET/CEP7":[238],"\u22654)":[239],"showed":[240],"clinically":[241],"meaningful":[242],"antitumor":[243],"rapid":[246],"durable":[248],"responses.":[249],"Crizotinib":[250],"generally":[252],"well":[253],"tolerated.":[254],"Coincidence":[255],"other":[262],"targets":[263],"is":[266],"being":[267],"explored.":[268],"Clinical":[269],"information:":[271],"NCT00585195.MET/CEP7":[272],"Category":[273],"Low":[274],"(N":[275,278,281],"=3)":[276],"Med":[277],"=14)":[279],"Hi":[280],"=20)":[282],"Response":[283],"evaluable":[284],"n":[285,288,291,311,317,323,330,336,341],"=":[286,289,292],"20":[293],"Objective":[294],"rate,":[296],"%a":[297],"(95%":[298,358],"CI)":[299],"33.3":[300],"(0.8,":[301,361],"90.6)":[302],"14.3":[303],"(1.8,":[304],"42.8)":[305],"40.0":[306],"(19.1,":[307],"63.9)":[308],"Complete":[309],"response,":[310,316],"0":[312,313,324,342],"Partial":[315],"6":[320,326],"Stable":[321],"disease,":[322],"Progressive":[327],"disease":[328],"(PD),":[329],"Early":[334],"death,":[335],"Indeterminate,":[340],"mo":[347,357],"(range)b":[348],"12.1":[349],"(12.1\u201312.1)":[350],"3.7":[351],"(3.7\u20133.7)":[352],"5.5":[353],"(3.3\u201325.8)":[354],"PFS,":[356],"CI)c":[359],"1.8":[360],"14.0)":[362],"1.9":[363],"(1.3,":[364],"5.5)":[365],"6.7":[366],"(3.4,":[367],"7.4)":[368],"aResponse-evaluable":[369],"populationbObjective":[370],"responderscBased":[371],"Kaplan-Meier":[373],"method":[374]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":14},{"year":2020,"cited_by_count":27},{"year":2019,"cited_by_count":14},{"year":2018,"cited_by_count":3}],"updated_date":"2026-10-03T13:16:28.481748","created_date":"2018-08-22T00:00:00"}